Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 9;9(7):600. doi: 10.3390/antiox9070600

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Total non-ferritin-bound iron concentrations resulting from 3 h pre-treatment with free-drug or P68 + DQA nanoformulated preparations of either 500 and 1000 μM NAC (N500, N1000), combined NAC with 50 or 100μM DFO (N500 + D50, N1000 + D100) or 100 μM DFO alone (D100) followed by 24 h treatment with 100 μM rotenone (R100) compared to R100 treatment alone. MEM represents the control condition where cells were only treated with media, no pre-treatment nor R100 treatment (mean ± S.D., n = 6). Total non-ferritin-bound iron was calculated using the total iron concentrations obtained from the ferrozine assay minus the mean ferritin concentrations obtained from the ferritin ELISA (see Supplementary Figure S2). * represents the significance of control or pre-treatment conditions compared to R100 treatment alone (** p < 0.01). # represents the significance of nanoformulated drug compared to free drug within the same treatment condition (# p < 0.05, ## p < 0.01).